Interpace Biosciences, Inc.
IDXG· OTC
IDXGInterpace Biosciences, Inc.
Filed Mar 27, 2023 · 10-K · 86 days after period end · 0001493152-23-009106
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $8.33M | $4.07M | $9.65M | $4.22M |
| Net Income | -$1.56M | -$3.73M | -$8.14M | -$10.66M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 27, 2023 · 86 d after period end
